A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 1/20/2010

Posted by | 4:31pm on Wednesday, January 20, 2010

:
Welcome to the pharma marketing & social media chat (#socpharm). Plse start w/intros. #socpharm 1/20/2010 19:04

:
Good evening, Eileen & everyone! Angela Dunn from Odom Lewis here. #socpharm

:
I’m Eileen, work for Siren Interactive & enjoy working with pharma companies to try & figure out how to use SM to help pts/hcps. #socpharm

:
Frieda Hernandez here from Siren Interactive in Chicago – Bus dev, strategy professional, relationship mktg & #socpharm

:
Gillette has 190,260 Facebook fans…Nexium has 461…I love my razor but really a heartburn med is a LOT more important #socpharm

:
@ That stat puts things in perspective. So even if pharma has built Facebook pages they aren’t driving ppl to them? #socpharm

:
We’ll assume that all tweets within #socpharm are your own & not your employers (unless you specifically declare them) #socpharm

:
Pharma seems to subscribe to the “if you build it they will come” perspective. Similar stats around YouTube channel usage. #socpharm

:
Fan pages built on brand loyalty, either U have fans or U don’t. Saw stat that less than 1% of FB fan pages have over 10,000 fans. #socpharm

:
@ But brands can do promotions that encourage fandom. #socpharm

:
@ Correction, 4% of FB Fan pages have over 10,000 fans. #socpharm

:
@ #socpharm I’m sorta lurking in the middle of dinner here

:
T1 @ did a great analysis of pharma Twitter accounts: http://bit.ly/7BKr79 So how is pharma doing? #hcsm #hcsmeu #socpharm

:
@ Lurking is always welcome :) #socpharm

:
@ Good analysis of big pharma Twitter follower, following and tweets on WhydotPharma http://bit.ly/90RmvO #socpharm

:
Gr8! Missed this 2day RT @ T1 @ did a gr8 analysis of #pharma Twitter accounts: http://bit.ly/7BKr79… #socpharm

:
@ Hello Sally, good to see you! #socpharm

:
@JNJComm @ @ @ have managed to build relationships with followers concludes @ #socpharm

:
T2: What’s your opinion on @ & use of J&J blog to communicate on this issue? http://jnjbtw.com #socpharm

:
Nonsense. If you build it and not promote it…it just sits there. #socpharm

:
@ Agree that promotion is an essential part of any web project. AND “feeding the beast” with new content/info. #hcsm #socpharm

:
RT @: @ Good analysis of big pharma on Twitter on WhydotPharma http://bit.ly/90RmvO #socpharm

:
Hey. Thanks for the update on the J&J recall. I was not aware. Good use of the blog, but tone was really corporate (n=1). #socpharm

:
Think it’s great that @ is using immediacy of Twitter to share message. #socpharm

:
@ Re: T2 – There are TWO comments on that post, one from a J&J employee. Clearly more engagement is needed. #socpharm

:
Agreed! RT @: Think it’s great that @ is using immediacy of Twitter to share message. #socpharm

:
@ T2: Surprising there aren’t more comments on JNJ blog re McNeil recall since it’s a hot topic & they allow negative ones #socpharm

:
Agree, as well. I like that it was part of a broader communication plan….an additional channel. Responsible, if you ask me. #socpharm

:
@ Good point, @ recall part of integrated multi-channel approach to handling crisis situation. #socpharm

:
Agree! Integrated multi-channel approach is key. #socpharm

:
T2: Anyone have any advice for @? What could they be doing better to handle PR situation? #socpharm

:
T3: Here’s unique topic: Novartis embraces “smart pills” http://bit.ly/6GmkrJ What do you think? #socpharm

:
T3: Are “smart pills” technology a great adherence approach or invasion of privacy? Will pts use them? http://bit.ly/6GmkrJ #socpharm

:
@ Joining late but the whydotpharma analysis is really interesting. #socpharm

:
T2 Corp comm is a tough job, channel is still evolving. I think J&J doing the best they can #socpharm

:
Just saw recall site Impressive they planned and had that infrastructure in place. They are ahead of most pharma. #socpharm

:
RT @ EileenOBrien T3: Here’s unique topic: Novartis embraces “smart pills” http://bit.ly/6GmkrJ What do you think? #socpharm

:
@CAVT Welcome Clarissa! Agree @ did a great job analyzing pharma & twitter. #socpharm

:
T3 How are smart pills/dispensers different from getting med reminders on mobile phone in terms of privacy? Both opt-in scenarios? #socpharm

:
Hi Eileen, thanks again for hosting this tweet chat. #socpharm

:
@tstitt Pleasure! As always u raise an interesting point. Somehow because smart pills report back on behavior seems more invasive? #socpharm

:
Smart pills! Adherence is a big issue with many interested players. Cool to link to a case manager to follow up, if needed. #socpharm

:
T3: If data remains between patient & physician – no problem. If pharma gets it – invasive #socpharm

:
T3 If I give evidence of med adherence via smart pills, do I still have to (effectively) pay for non-adherence by others? #socpharm

:
@ What if I opt-in to giving pharma & retail pharma my smart pill data b/c I get co-pay discounts/better tiers? #socpharm

:
@ Your smart phone tells everyone where you are…seem invasive? Playing devil’s advocate here… #socpharm

:
Hi there! #socpharm

:
@ And I use @ so I volunteer where I am to almost everyone! #socpharm

:
#socpharm just joined and as i posted my tweet about the intelligent pill I see this discussion #socpharm

:
@ Welcome to the chat! We are talking about smart pills: http://bit.ly/6GmkrJ #socpharm

:
@ Talk about perfect timing! What do you think about smart pills? #socpharm

:
Not invasive if agree to up front. Better health outcomes have their place. Agree that no penalty for non-adherence is needed #socpharm

:
@ Wouldn’t you want to be the Mayor of <smart pill med name goes here> Adherence with all the attendant benefits? #socpharm

:
these pills are taken to treat patients, so if docs can get early warning signs and the data is safe and secure – I am all for it #socpharm

:
LOL RT @ @ Wouldnt u want to be the Mayor of <smart pill med name goes here> Adherence w/all attendant benefits? #socpharm

:
it also encourages adherence – knowing that big brother is watching #socpharm

:
T3 For more analysis on this see WSJ http://bit.ly/11Fpce #socpharm

:
More on “smart pills” RT @ T3 For more analysis on this see WSJ http://bit.ly/11Fpce #pharma #socpharm

:
@ But now we *all* pay for the non-adherent cohort in our premiums/costs of care. Can smart pills change that? #socpharm

:
intelligent pill – eliminates waste (drug spend) #socpharm

:
@ How about an opt-out option for smart pills? What if I don’t want a new technology along with my meds? #socpharm

:
@ I read about it and I think it’s an amazing technology, not only for usual treatments but for clinical trials #socpharm

:
@ so far all positive, but I am also very open with my health info and do not believe that privacy exists. #socpharm

:
@ It will be interesting to see how/if this evolves. Think pts would have to have a choice. Would only adherence pts choose? #socpharm

:
For me, it’s all about the health outcomes. Not best used for all drugs conditions. I’d be sensitive daily Cialis use tracking #socpharm

:
@ My fav story abt health records/privacy: worked w/doc who put charts on top of car & drove away, paper flew down st #socpharm

:
Good point on the clinical trials. Transplant also comes to mind. Compliance/adherence key #socpharm

:
@EileenOBrien I think choice will be important and I agree that this would be perfect for clinical trials as it ws mentioned #socpharm

:
RT @: re Q3 I feel vaguely uneasy abt the whole concept, but I might opt in if there was sufficient incentive #socpharm

:
crazzy thought – but what about healthplan premium reductions if you can show adherence and prevent hospitalizations -opt in model #socpharm

:
@EileenOBrien Could see how smart pill technology could be useful for family members who take care of patients w/ chronic disease. #socpharm

:
Thanks SO much for joining in tonight. See you next Wed at 8 pm est. If u have any topic ideas please send them my way. #socpharm

:
@ @ what kind of incentive would you want? how about premium reductions? #socpharm

:
@EileenOBrien just when i started to have fun. hope i can join in next Wed. thanks for organizing. #socpharm

:
@ Even those who might not be able to remember if meds taken. Lots of interesting possibilities. #socpharm

:
@ Thank you, Eileen! Are topics for #socpharm posted anywhere in advance of the chat? #socpharm

:
Sounds good 2 me RT @: @ @ what kind of incentive would you want? how about premium reductions? #socpharm

:
@ Thanks again Eileen. Very stimulating as usual #socpharm

:
It’s about health, not money. Amazing added value programs could be created (opted in). Could place your drug on pref formulary #socpharm

:
@ Thx! Next time I expect to join earlier ;-) #socpharm

:
@ Thank you for hosting the chat! Glad I could make it for the last few minutes. #socpharm

:
@ Usually come up w/them a few hrs before, but that’s a gr8 idea. I should tweet t& post to http://socialpharmer.ning.com #socpharm

:
This was a blast. Thanks to all (and GREAT links, btw) #socpharm

:
Transcript from tonight will be posted to http://socialpharmer.ning.com. Great community if you haven’t joined it. #socpharm

:
@chiah @ Thanks for sharing your insights. #socpharm

:
@EileenOBrien THX! Will look for it & read before next week’s chat- http://socialpharmer.ning.com Uhad some gr8 resources tonight. #socpharm 1/20/2010 20:11

:
My pleasure! RT @: @ @ Thanks for sharing your insights. #socpharm 1/20/2010 20:12

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com